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Spectroscopy (FCS) can be performed using the GUV model to extract information on mobility and
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Biological bilayers, such as plasma membranes, offer a unique
platform in which a dynamic arrangement of lipids regulates the
molecular interactions involved in cellular functions. Small changes
such as cholesterol content and ﬂuidity could induce growing or
coalescence of microdomains that, as a consequence, favor preferen-
tial partitioning of proteins involved in cellular signaling events
critical to cell viability [1]. In vivo, lipid rafts have been postulated to
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[2–6] associated with important biological processes such as
endocytosis, signaling, protein transport, apoptosis, and cytoskeleton
organization [7].
Tomaintain cell viability, there exist speciﬁc pathways that control
membrane composition; one of them is the reverse cholesterol
transport (RCT) pathway, the mechanism by which excess cholesterol
is removed from peripheral cells [8,9]. In order to occur efﬁciently,
apolipoproteins as apolipoprotein A-I (apoA-I) must interact with key
components at the plasma membrane in a process that is strongly
dependent on protein conformation and membrane composition and
heterogeneity.
This article reviews the use of ﬂuorescence microscopy method-
ologies in the analysis of apoA-I and HDL interactions with artiﬁcial
and natural membranes, as an example of the use of microscopy on
this type of system.
2. The RCT cycle: apoA-I and reconstituted HDL particles (rHDL)
interaction with membranes
Cholesterol is a key lipid component of biological membranes, and
its content and partitioning between raft and more ﬂuid domains can
be modiﬁed in order to regulate several cellular processes as enzyme
activity, signal transduction, opening/closing of channels [10], etc. By
the Reverse Cholesterol Transport (RCT), human HDL transports
excess cholesterol from peripheral tissues to the liver for excretion
into bile and feces [11]. Many steps in the RCT are under investigation
as possible therapeutic targets, in order to improve cholesterol efﬂux
and thus reducing cardiovascular risk.
Even though the RCT pathway is not completely understood, it is
believed that the ﬁrst steps involve the interaction of lipid-free or
lipid-poor apolipoproteins (for instance apoA-I) with the ATP Binding
Cassette transporter ABCA1 at the plasma membrane. This event
initiates the efﬁcient removal of cholesterol and phospholipids,
promoting the apoA-I rearrangement into disk-shaped particles
(preβHDL). This process is unidirectional and requires ATP as an
energy source, mediating not only removal of plasma membrane
cholesterol but its mobilization from internal pools as well [12]. The
preβHDL particles further remove lipids very efﬁciently from the
plasma membrane, probably involving different mechanisms such as
acceptors of spontaneously solubilized cholesterol, or speciﬁc inter-
action of apoA-I with other membrane proteins, such as ABCG1 [13].
Lipidated products serve as substrates for plasma Lecithin Cholesterol
Acyltransferase (LCAT), and other lipid transfer proteins giving rise to
circulating, mature HDLs, which are recognized by liver receptors and
thus catabolized [14]. Passive diffusional lipid removal by HDL also
contributes to ensure the efﬁciency of cholesterol homeostasis.
In support of the function mentioned for HDL in RCT, a substantial
body of evidence agrees that high levels of circulating HDL inversely
correlate with the risk of developing cardiovascular disease (CVD) [15].
Nevertheless, the efﬁciency of HDL to solubilize cholesterol, and/or to
interact with key components of the RCT pathway, is strongly
dependent on HDL particle stability, size, and chemical integrity
[16,17]. HDL lipids and proteins can be subjected to cellular environ-
ments that induce oxidation, glycation, or other modiﬁcations,
especially during systemic inﬂammation, diabetes, and chronic renal
or coronary heart disease. In these cases, HDL becomes dysfunctional
and losesmanyof its atheroprotective roles suchas LCATactivation [18],
inhibition of LDL oxidation [19], cholesterol efﬂux [20], etc. Thus, newer
research suggests that the “dynamic ﬂux” of macrophages-derived
cholesterol through the RCT pathway is more important to determine
risk of CVD than the steady-state concentration [11], and that thequality
of the lipoproteins, rather than the quantity, should be considered in
order to establish the predictable protective role of HDL [19].
In addition, the efﬁciency of apoA-I interaction with membranes
and lipid removal depends not only on protein conformation but alsoon the heterogeneity of themembrane, which is believed to play a key
role in the regulation of some of the steps involved [21]. Despite their
enrichment in cholesterol, lipid rafts do not seem to be essential for
lipid efﬂuxmediated by apoA-I, since it was suggested that cholesterol
is preferentially acquired from the loosely packed, “non-raft” micro-
domains [22,23]. Thus, it was proposed that one of the functions of the
ABCA1 should be to induce a redistribution of cholesterol and
sphingomyelin from rafts to non-rafts domains in order for them to
be accessible to acceptors [21]. These studies support the following
hypothesis: “the interaction of apoA-I and HDL with the cellular
membrane, and its capacity to remove phospholipids and cholesterol
is dependent on the composition and distribution of lipid domains in
the plasma membrane”.
By visualizing artiﬁcial models, we studied different aspects of
these interactions using two-photon ﬂuorescence microscopy. Ana-
logs of the preβHDL containing apoA-I and different molar ratios of
lipids have been reconstituted, and interactions with model bilayers
and cells were observed and quantiﬁed; our results clearly show that
protein binding to bilayers is dependent on both protein conformation
andmembrane composition; we discuss here published and new data
and the extrapolation of the in vitro data to in vivo systems with
possible implications.3. What can microscopy teach us about the apoA-I/HDL–
membrane interaction?
3.1. Models for microscopy studies and ﬂuorescence microscopy
techniques
Although most of the lipid models systems available (SUVs, MLVs,
LUVs, etc) can be used in microscopy studies, the most appropriate
systems are planar membranes [24] and Giant Unilamellar Vesicles
(GUVs), since they allow spatial resolution and visualization. This
work is focused on the use of GUVs as model systems.
GUVs are constructed by the electroformation method published
by Angelova and Dimitrov in 1986 [25] and the methodology
published by Pott et al. [26,27], which allows GUVs to be grown at
higher salt concentrations required for protein studies in solution.
GUVs can be produced from pure lipids, lipid mixtures, natural
lipids extracted from cells, and also from entire membranes contain-
ing proteins and lipids. We will refer here to the methodologies and
techniques used to study the inﬂuence of lipid segregation in the
lipid–protein interaction, therefore most of the mixtures used show,
under certain conditions of temperature and lipid composition, phase
separation visible under the microscope.
Studies of lipid–protein interaction using systems that show
separation of macrodomains address the hypothesis that in vivo
membranes are heterogeneous and present segregation of lipid
domains. Studies on cells indicate that the major portion of the
plasma membrane is in the liquid-ordered state [28]; instead, the raft
theory states that heterogeneity in the membrane is due to the
existence of areas with ordered packing (lo phase) in a more ﬂuid (ld)
continuous phase. This idea comes from the discovery that glyco-
sphingolipids cluster in the Golgi apparatus before being sorted to the
apical surface of polarized epithelial cells [2,29] and experiments
showing that glycosphingolipid clusters tend to be insoluble in Triton
X-100 at 4 °C, forming detergent resistant membranes (DRM) rich in
both cholesterol and glycosylphosphatidyl inositol (GPI)-anchored
proteins [30]. Rafts are theoretical structures postulated to exist in
cellular membranes of similar compositions and phase (lo) of DRMs in
equilibrium with the rest of the membrane in a more ﬂuid phase (ld).
Based on the composition of the DRMs, synthetic mixtures called raft-
like mixtures are used to reconstitute model membrane systems
where lipid phases coexist [31–35], in order to study the inﬂuence of
phase segregation on protein–lipid interaction. Fig. 1 shows a diagram
Fig. 1. Schematic representation for the experimental protocols used in the studies of lipid–protein interactions in Giant Unilamellar Vesicle system presenting phase coexistence.
(A) Binding experiments are performed adding labeled protein to the chamber containing the GUVs. After the incubation period, the protein may preferentially bind to one or both
types of domains. Different ﬂuctuation techniques (described in the text) can be used to quantify the binding. Circular objects represent the top view of the GUV presenting lipid
domains. (B) Laurdan GP imaging is used to detect changes in water content (related to membrane ﬂuidity) in the lipid bilayer due to the interaction with proteins. After the
interaction, the GP changesmay occur in the two phases or in one of them, both the GP value and the size of the domain can be quantiﬁed and give information of the interaction. The
ring shapes represent the GP image of a GUV taken at the equatorial plane and presenting domain separation (two different colors represent two macrodomains with different GP
value), this conﬁguration is preferred for GP quantiﬁcation because all the Laurdanmolecules (located parallel to the lipids) are excited by the circular polarized light usually used for
excitation.
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Protein binding (Fig. 1A). GUVs presenting macrodomain separa-
tion can be used to assess the binding of a protein to a speciﬁc
macrodomain. The protein under study (labeled with a ﬂuorescent
molecule) is added to the chamber containing the GUVs, and after the
appropriate incubation period, measurements assessing for binding
are performed. Several techniques are suited to extract information
about binding: the ﬁrst qualitative answer is given simply by
ﬂuorescence intensity measurements: in this case the intensity
image can show homogeneous or domain-speciﬁc binding and the
imageswill show a sphere (the GUV) totally ﬂuorescent or ﬂuorescent
in some speciﬁc areas (see Fig. 1A, Possible Qualitative Answers). To
assess the lipid phase where the protein preferentially binds, a
membrane probe such as Laurdan or Prodan can be added to the same
GUV after the binding has occurred, or if a dual emission channel
system is available, the lipid phase is measured in one channel and the
binding is measured in the other channel using ﬂuorescent dyes with
good emission spectral separation and the appropriate ﬁlters [36–38].
In addition, ﬂuctuation techniques can be used to quantify the
binding afﬁnity, including Fluorescent Correlation Spectroscopy
(FCS), scanning FCS (sFCS), Raster Image Correlation Spectroscopy
(RICS), and Number and Brightness Analysis (N&B). FCS [39–43]
measures the ﬂuctuations in ﬂuorescent intensity in a small volume
generated by a pinhole in confocal microscopes or by the two-photon
excitation process [44–46]. Fluctuations due to diffusion of the
molecules in and out of the small volume are detected as a function
of time and the Autocorrelation Function (ACF) Analysis gives the
diffusion coefﬁcient (Dcoef) and the average number of particles in the
observation volume (Ň). The ﬂuctuation can also be analyzed using
PCH [47], where the probability of detecting photons per sampling
time is calculated and thus the number of molecules in the
observation volume (N) together with its molecular brightness (β)
is extracted. FCS measurements on the coexisting macrodomains of
the GUVs can report the mobility (Dcoef) and the number of molecules
of bound and free protein allowing the estimation of the dissociation
constant. Scanning FCS [48] gives the same information as point FCSwith the big advantage of allowing sampling of several points at the
same time, and permits one to discriminate ﬂuctuations coming from
the movement of the GUV itself by cross-correlation analysis of points
separated in space [49–51]. RICS [52] provides the same dynamic
information as FCS as well as information on the spatial correlation
between points along the scanning path. As the laser performs the
raster scanning movement, it creates a space–time matrix of pixels
within the image. The temporal and spatial sampling of the laser beam
during the raster scanning is known, that is, the time the laser samples
each pixel (pixel dwell time); the time between scan lines (line time);
and the time between images (frame time). Therefore, the images
contain information on the microsecond time scale for pixels along
the horizontal scanning axis, millisecond time scale along the vertical
scanning axis or between scan lines, and on the subsecond to second
or longer time scale between successive images. This technique can
providemaps of the diffusion coefﬁcient and the number of molecules
of the bound and free species. Number and Brightness (N&B) Analysis
is based in moment analysis, for each pixel in an image stack [53,54].
From the average intensity in each pixel and the variance of the
intensity distribution, the number and brightness (aggregation) of
mobile particles is determined, thereby providing a new contrast
mechanism in the images based on a molecular property. If the
protein of interest aggregates when it binds to the membrane, this
technique can accurately detect oligomerization [55].
Furthermore, all these techniques performed in a two-channel
emission setup allow one to correlate protein binding and membrane
phase and to ascertain the protein binding stoichiometry, etc. [56–58].
If the GUVs have been constructed with a ﬂuorescent protein
integrated to the bilayer, the same techniques will provide valuable
information on motility and aggregation state of the protein
immersed in the membrane [27,59].
Changes in membrane phases (Fig. 1B). GUVs presenting lipid
segregation can also be a good model to study the properties of lipid
bilayers during protein interaction. Valuable information is given by
the ﬂuorescent dye Laurdan, used as a membrane probe because of its
large excited state dipolemoment, which results in its ability to report
the extent of water penetration into the bilayer surface due to the
1402 S.A. Sánchez et al. / Biochimica et Biophysica Acta 1798 (2010) 1399–1408dipolar relaxation effect [60]. Water penetration has been correlated
with lipid packing and membrane ﬂuidity [61,62]. The emission
spectrum of Laurdan is centered at 440 nm if the membrane is in the
gel phase and at 490 nmwhen it is solubilized in the liquid crystalline
phase. The Generalized Polarization (GP) value, deﬁned as the
difference of intensities at 440 minus 490 nm divided by the sum,
measures the emission shift. To calculate the GP value in a two-photon
microscope (to avoid photo-bleaching), an excitation wavelength of
780 nm and a two-channel system with the corresponding ﬁlters on
the emission are used [31,63].
In a GUV presenting phase separation, the emission of Laurdanwill
depend on the water content of each phase: the emission from a ﬂuid-
ordered phase is blue shifted, as compared with the emission from the
ﬂuid-disordered domain. In this way, spatial identiﬁcation of coex-
isting phases can be realized directly from the GP image. Thus,
Laurdan GP imaging [31,63,64] can quantify and localize changes in
the packing of the lipids in the bilayer due to protein binding,
cholesterol removal, etc. GP images are usually taken in the equatorialFig. 2. ApoA-I interaction with heterogeneous membranes. (A) Membrane heterogeneities ex
GUV at 24.5 °C attached to the platinumwire (structure on the right). (B, C) Lipid solubilizatio
in volume of the GUV as comparing the Laurdan intensity image (B) before and (C) after incu
of DMPC:DSPC (0.35:0.65 molar ratio) at 42 °C. A target GUV was chosen using the CCD ca
background signal ∼150 total counts (image not shown). After 2-h incubation with Alexa488
GUV, which indicates protein binding. Next, Laurdan was added to the chamber (ﬁnal
heterogeneities existing on the membrane (total counts increased 10 times with respect to
correlate with the membrane heterogeneities. No changes in the size of the GUV occurred a
microscope previously described [68,70]. For both probes (Alexa488 and Laurdan) excitation
broad band-pass ﬁlter from 350 to 600 nm (BG39 ﬁlter, Chroma Technology, Brattleboro, Vplane of the GUV [31,63]; in this conﬁguration, all the Laurdan
molecules located parallel to the phospholipids can be excited with a
circular polarized light (Fig. 1B). Under this condition, the GP images
can be processed and the macrodomains separated and studied
independently. The areas of each macrodomain can be quantiﬁed to
study speciﬁc morphological changes associated with the interaction.
These methodologies have been used for the study of several proteins
[36–38,55,65–67] and the apoA-I/HDL system [68–72].
3.2. ApoA-I interaction with heterogeneous membranes
The idea that the interaction of apoA-I with membranes is favored
by bilayer irregularities was suggested in 1978 by Pownall et al. [73]
following the interaction of apoA-I with multilamellar DMPC
liposomes by light scattering. The data showed a decrease in light
scattering of the DMPC MLVs after addition of apoA-I (interpreted as
lipid solubilization) only at 24.8 °C; the authors concluded that this
behavior arises from the formation of a “structural determinant”isting at the transition temperature [63]: Laurdan intensity image (top view) of a DMPC
n fromDMPC:DSPC 1:1 GUV by apoA-I occurs at 28 °C [68] as evidenced by the decrease
bation with apoA-I for 2 h. (D–F) ApoA-I binding to heterogeneous bilayers: a GUVmade
mera and the control image taken before the addition of the labeled protein showed
-apoA-I, the (D) intensity image showed ∼130,000 total counts deﬁning the shape of the
concentration of 0.76 μM) and the same target GUV was imaged (E) revealing the
D). (F) The overlapping of (D) and (E) showing that binding of the protein does not
t this temperature after adding apoA-I. Experiments were performed in a two-photon
wavelength of 780 nmwas used and the ﬂuorescence emission was observed through a
T). Blue–red color scale is used for Laurdan intensity images and red for Alexa488.
Fig. 4. Kinetics of cholesterol removal by particles of 96 Å of wild type apoA-I rHDL
(circles) [69] and of the mutant H1@H4 (squares) at 36.5 °C from POPC-30% cholesterol
GUVs. Solid line for the opened circle symbols corresponds to a ﬁrst-order exponential
decay ﬁt with a time constant of 39.3±0.1 min. GP images of the GUV at the beginning
(top left) and end (bottom right) of the incubation time are also shown and colored
according to the GP scale going from −1 to 1.
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determinant was necessary for the efﬁcient interaction. Later in 2007,
two-photon microscopy studies done by our group showed that this
“determinant” indeed exists at the phase transition of DMPC [63].
Fig. 2A shows the top view intensity image of a DMPC GUV at 24.5 °C
(similar image of the already published [63]). Close to the transition
temperature of DMPC, the lipid molecules in gel and liquid phases
coexist and there is a large area of defects. The particular bilayer state
existing at the transition temperature is characterized as having high
stress, which induces volume and shape changes [74] and high
permeation to small molecules [75]. This state could allow deeper
penetration of some of the amphipatic helices of apoA-I, inducing a
conformational rearrangement in the protein in which the hydro-
phobic faces of the helices come into close contact with the acyl chains
of the lipids favoring their removal.
In the interaction of apoA-I with binary mixtures, the efﬁciency of
lipid removal is also dependent on a special membrane condition.
Scattering measurements for MLVs of DMPC:DSPC also show a
particular temperature at which lipids are solubilized (28 °C) [76].
In this regard, we have used DMPC:DSPC 1:1 molar ratio GUVs, and
demonstrated that domain segregation is not the important factor for
lipid solubilization by apoA-I. In these liposomes, domain coexistence
is present from ∼50 to 24 °C but effective lipid solubilization only
occurs at ∼28 °C [68]; this fact is detected by a decrease in the size of
the GUV after addition of apoA-I (Fig. 2B and C) as a consequence of
solubilization of both lipids from the binary mixture, but with higher
preference for the more ﬂuid component [68].
The preferential binding of apoA-I to areas of different lipid packing
was assessed using Alexa488-labeled apoA-I (Alexa488-apoA-I) and
GUVs of DMPC:DSPC (0.35:0.65 molar ratio) at 42 °C (temperature
where phase coexistence exists). A target, unlabeled GUVwas localized
using aCCD camera andAlexa488-apoA-Iwas added to the chamber to a
ﬁnal protein concentration of 10 µg/ml. After 2-h incubation, the
intensity image (Fig. 2D) shows the GUV deﬁned by the brightness of
labeled apoA-I, indicating the binding of the protein to the bilayer. Next,
Laurdanwas added to the chamber and the same GUVwas imaged. The
Laurdan intensity image (Fig. 2E) evidences a membrane topology
similar to the “structural determinant” associated with coexisting gel
and liquid crystalline phases on DMPC (Fig. 2A); in this mixture the
irregularities can be attributed to the coexistence of theDMPC andDSPC
molecules, which at 42 °C are over and below their transition
temperatures, respectively (Tm DMPC=24 °C, Tm DSPC=55 °C;
Fig. 2E). Fig. 2F shows the overlapping of Fig. 2D and E evidencing the
fact that apoA-I binding is not dependent on the lipid packing.
Similar results of homogeneous binding were obtained on POPC:
SM:FC GUVs presenting phase separation [72]. Fig. 3 shows a diagram
with the main conclusions of our published studies on the interaction
of lipid-free apoA-I and membranes in vitro [63,68,70,72]: apoA-I is
able to bind to the lipids in a homogeneous lipid phase (Fig. 3A, [64])Fig. 3. Scheme of the different interactions of lipid-free apoA-I with membranes analyz
phospholipid bilayers results in high binding but non-efﬁcient lipid removal [70]. (B) Efﬁcie
small ﬂuid domains nucleated within a continuous gel phase [68]. In the diagram, the blue ri
in disordered state (white) and ordered state (gray), respectively.but effective lipid solubilization occurs only under particular condi-
tions: either at the transition temperature of a pure lipid or where the
membrane is composed of small ﬂuid domains nucleated within a
continuous gel phase (a few degrees above the melting temperature
of the more liquid component in a binary mixture); under these
conditions interfacial packing defects are maximal (Fig. 3B) [68].
3.3. Cholesterol efﬂux and Laurdan GP
ApoA-I constitutes ∼70% of the protein moiety of HDL and its
conformation is highly ﬂexible in order to rearrange in response to
changes in HDL lipids during catabolism. Human apoA-I contains a
series of highly homologous 11- and 22-residue amphipathic α-
helices. These amphipathic α-helices are deﬁned by the arrangement
of positively and negatively charged amino acids on the helical polar
face as classes A and Y. Helix 1 is a Class A helix together with helices 2
and 5–8, which have positively charged amino acids surrounding the
non-polar face with negative residues clustered at the center of the
polar face. Helices 3–4 and 10 are class Y helices, organized similarly
but having a positive charge disrupting the negative cluster [77].
Mutants lacking helix 10 show lower rates of cholesterol efﬂux and
recently Panagotopulos et al. [78] have shown that helix 10 is critical
for promoting optimal cholesterol efﬂux via the ABCA1 pathway fromed by our technical approach. (A) Lipid-free apoA-I interaction with homogeneous
nt lipid solubilization occurs from bilayers having high interfacial packing defects, with
bbon represents the lipid-free apoA-I, circles with two legs represent the phospholipids
Fig. 5. Interaction of rHDL with phase coexisting GUV. (A) Diagram of the target GUV
attached to the Pt wire. (B) GP image of the target GUV (top view) of DOPC:DPPC:FC
(1:1:1 molar ratio) at 24.8 °C presenting lo (orange) and ld (light green) separated
phases, a small GUV on the top right can also be seen and the discontinuity on the right
shows the place of attachment of the GUV to the platinumwire. For GPmeasurements, a
GP image is taken on the center of the same target GUV and the GP values for each phase
are shown in the ﬁgure (C) at time zero and (D) after 60-min incubation with 10 μg/ml
96 Å rHDL [69]. False color representation according to the palette with GP values going
from −1 to 1 is used.
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afﬁnity [79].
As circulating HDL are composed of an heterogeneous and dynamic
group of particles with different sizes, shapes, and compositions,
models have been created in order to understand the conformational
arrangement of apoA-I involved in lipid homeostasis. Thus, homoge-
neous lipoprotein complexes homologous to the preβ HDL particles
observed as the ﬁrst intermediates of cholesterol solubilization [80]
have been reconstituted (rHDL) with apoA-I and different amounts of
cholesterol and phospholipids. These particles can be obtained by the
sodium cholatemethod [70], or by spontaneous solubilization of lipids
at the transition temperature.
The organization of apoA-I in the rHDL has been reviewed before
and three models have been proposed: the picket fence [81], the belt
[82], and the hairpin models [79]. Förster Resonance Energy TransferFig. 6. Scheme of the interaction of lipid-bound apoA-I (rHDL) with membranes analyzed
cholesterol from homogeneous bilayers as independent units and growing in size accordin
packing (lo/ld), rHDL preferentially remove phospholipids and cholesterol from the more dis
in disordered state (white) and ordered state (gray). Black elliptical shape with one leg rep(FRET) data from our previous studies strongly support the hairpin
arrangement of apoA-I in these HDL complexes [83]. The threemodels
agree that helices 10 and 1 are directly involved in the interaction of
the HDL particles with the lipids in the bilayer. In order to determine
the importance of helix 1 for protein interaction and cholesterol
solubilization from membranes, we used an apoA-I mutant, H4@H1,
having the putative high-lipid afﬁnity helix 1 replaced with a second
copy of a lower lipid afﬁnity helix 4 [84] but which still has helix 10 in
its normal location at the C terminus. The lipid-free mutant exhibited
cholesterol efﬂux capabilities similar to Wt (wild type) on RAW
macrophages; however, it exhibited markedly reduced (50%) lipid
association characteristics in the DMPC clearance experiments.
Reported changes in GP values of GUVs of POPC-32%cholesterol
incubated with 78 Å rHDL containing Wt apoA-I demonstrated that
rHDL efﬁciently remove cholesterol from the lipid bilayer [69]. FCS
data on the same system showed that the 78 Å rHDL interact with the
bilayer as independent units (constant number of particles) and that
their size increase (Dcoef decrease) to 96 Å, results also consistent with
lipid removal [70,85]. Fig. 4 shows the comparison of the GP changes
observed on POPC-32% GUV incubated with equal concentration of
rHDL containing the Wt apoA-I and the H4@H1 mutant (with altered
helix 1). Changes in the GP values during the incubation with the wild
type protein rHDL are consistent with published data [69]; however,
no changes in GP were observed during 2-h incubation of POPC-32%
FC GUVs with the mutant rHDL (Fig. 4). The lipid-free H4@H1
exhibited cholesterol efﬂux capabilities similar to Wt from RAW
macrophages; however, as expected, it exhibited markedly reduced
(∼50%) lipid association characteristics in the DMPC clearance
experiments. It could be possible then that lipid association is
important in order to facilitate passive cholesterol diffusion through
the aqueous medium.
3.4. HDL interaction with membranes having coexisting phases
In the process of cholesterol removal by HDL, the extent and
direction of the net cholesterol movement will depend on the ratio of
efﬂux to inﬂux and is determined by the properties of the acceptor (the
HDL particle) and the donor (the membrane) [86]. Factors reducing
the packing density of lipid molecules have been proposed to enhance
the rate of cholesterol transfer [87]. Results from “raft-like” mixtures
show that HDL particles preferentially remove cholesterol from lipid
domains characterized as liquid disordered (ld) [69]. Fig. 5 shows the
results obtained using Laurdan GP imaging to study the interaction of
DOPC:DPPC:FC (1:1:1 molar ratio) and rHDL at 25 °C. At this
temperature, the phase diagram indicates that liquid-ordereddomains
(lo, rich in DPPC) coexist with ld domains (rich in DOPC), with
cholesterol partitioning between the two phases [88]. Laurdan GP can
differentiate lo from ld phase and Fig. 5B shows them in different colors
(lo in orange and ld in light green); rHDL were added to the GUV atby our technical approach. (A) rHDL interact with and solubilize phospholipids and
g to FCS measurements. (B) If cholesterol is distributed in two phases with different
ordered (ld) domain [69]. As in Fig. 3, circles with two legs represent the phospholipids
resents the cholesterol molecules.
Fig. 7. GP imaging in alive cells. (Top) Human red blood cells were labeled with 1 μM Laurdan for 15 min and imaged at 37 °C. (A) Laurdan spectral image corresponding to the
overlapping of 19 images taken simultaneously at different emission wavelength while exciting Laurdan at 780 nm (taken in a Zeiss Meta 710). (B) Normalized emission spectrum of
Laurdan in the erythrocyte membrane taken from the area encircled in red in (A). (Bottom) Using SimFCS, the pixels in the GP image can be separated in those located inside the cells
(low GP) and the ones corresponding to the plasma membrane (high GP). Analysis for (C–E) human erythrocytes and (F–H) HeLa cells are presented.
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and after (Fig. 5D) 1-h incubation period. The GP value of the ld phase
decreased from0.1 to 0.02, indicating cholesterol removal, while the lo
remained unchanged [69]. Contrary to lipid-free apoA-I that requires a
high surface of domain coexistence to remove lipids [68], lipid
solubilization toward rHDL depends on the accessibility for cholesterol
(deﬁned by the particular characteristic of the lipids present at the
bilayer). The diagram in Fig. 6 shows the possible underlyingprocess of
the interaction of rHDLwithmembranes containing cholesterol. In the
POPC:FC (32%) (Fig. 6A), the unsaturations present in the acyl chains of
POPC introduce kinks that limit the ability of cholesterol to order, to
mix homogeneously, to reduce interfacial elasticity [89], and to lower
the in-plane elasticity [90]. Cholesterol locates more superﬁcially and
thus desorbs better from the membrane to the aqueous interface and
transfers to the rHDL. A similar situation is observed in the coexisting ld
phase in the DOPC:DPPC:FC (1:1:1) system. The ld phase is enriched in
the unsaturated phospholipid (DOPC) [88] and the kinks on the acyl
chains facilitate the transfer of cholesterol and phospholipids to the
rHDL (Fig. 6B). On the other hand, the coexisting lo phase is formed
mainly by DPPC, which contains a chain structural motif similar to
natural sphingolipids [89]. It has been suggested that cholesterol
molecules can locate in this type of bilayer with part of their tail in the
adjacent leaﬂet [91] allowing formation of tail-to-tail dimers [92], and
then impeding its desorption (Fig. 6B).
3.5. HDL interaction with cell membranes
Visualization of protein interactions with lipid domains in vivo is
difﬁcult due to the fast dynamics of lipid arrangement in membranes
and the lack of methodologies to visualize membrane heterogeneity
[5]. Thus, the most common methodologies used to study this type of
interactions are the isolation of detergent resistant membranes
(DRMs) [10] and the use of ﬂuorescent dyes on ﬁxed cells [28]. In
the Keystone Symposium on Lipid Rafts and Cell Function in 2006
[93], rafts were deﬁned as “small (10–200 nm), heterogeneous, highlyFig. 8. Effect of cholesterol acceptors on the GP membrane of alive cells. (A) GP membrane
120 min, and incubated with 96 Å rHDL 300 µg/ml for 2 h. Buffer used: 10 mM phosphate, 1
(Control), incubated with MβCD 10 mM for 60 min and incubated with 96 Å rHDL 300 µg
number of cells analyzed. ANOVA test was performed to compare the control data and the d
with pb0.05. Images presented correspond to the complete GP image. Palette shows the codynamic, sterol- and sphingolipid-enriched domains”. Laurdan GP
imaging have been used in the search for cell membrane heteroge-
neity in erythrocytes [94,95] and macrophages [96].
Erythrocytes are well-studied systems. Human erythrocytes were
labeled with 1 µM Laurdan and Fig. 7A shows the spectral image
corresponding to the overlap of 19 images taken simultaneously at
different emission wavelengths while exciting Laurdan at 780 nm.
Fig. 7B shows the spectrum corresponding to Laurdan inside the
erythrocyte membrane. The spectrum centered at 440 nm indicates
that membrane lipids are in an ordered phase in this system. In a
microscope, a GP image (Fig. 7C) is obtained using two-photon
excitation at 780 nm, two interference ﬁlters in the emission centered
at 440 and 490 nm, and applying the GP formula pixel by pixel [31,63].
The GP image of human erythrocytes in Fig. 7C shows areas in the
cells with different GP values. Using the SimFCS program (www.LFD.
uci.edu), the pixels with low GP values (−1bGPb0.3) corresponding
to the interior of the cells (Fig. 7D) can be separated from the pixels
with high GP values (0.3bGPb1) corresponding to the plasma
membrane (Fig. 7E). The GP image corresponding to the plasma
membrane (Fig. 7E) shows no visible macrodomain separation in
agreement with previous results reported by Bell's group [94,95].
Fig. 7F shows the GP image of a nucleated cell (HeLa cell) labeled with
1 μM Laurdan. The separation of the pixels corresponding to the
cytosol (Fig. 7G) and the ones from the membrane (Fig. 7H) also
indicate the lack of macrodomain separation in themembrane of HeLa
cells (Fig. 7H). Interestingly, the nuclear membrane cannot be
distinguished from the rest of the cytosol indicating that the nuclear
membrane is more ﬂuid than the plasma membrane.
It seems to be an apparent contradiction between the data
presented here reporting the lack of macrodomain separation in cell
membranes and data reported by Gaus et al. [96]. These authors
reported the 3D projection GP image of a macrophage showing
extended areas with high GP values localized in knob-like membrane
protrusions. The authors discussed that these areas could be either
large rafts exclusive of this cell type, or areas enriched in small raftsvalues for human erythrocytes in buffer (Control), incubated with MβCD 3.5 mM for
47 mM NaCl, 3 mM KCl, pH 7.4. (B) GP membrane values for HeLa cells in culture media
/ml for 2 h. Temperature for all the experiments was 37 °C and N corresponds to the
ata after incubation with the cholesterol acceptors. Results show a signiﬁcant difference
lor scale used for all the images.
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macroscopic regions of different GP. Most cells present evaginations,
ﬁlopodia, and protrusions. In the 3D projection, these areas appear to
have consistently higher GPs than in the rest of the cell. When we
carefully separate the protrusions from the rest of the plasma
membrane, we found that pixels belonging to the non-protrusive
part of the plasma membrane are relatively homogeneous in GP value
without evident separation into macroscopic domains. The fact that
macrodomains are not visible by GP imaging in the relatively ﬂat part
of the plasma membrane does not exclude the existence of domains
smaller than the pixel size. If these domains are also highly mobile
[93], other techniques capable of capturing the fast dynamics will be
needed to visualize them [5,50].
We report here the use of these two cellular systems (erythrocytes
and HeLa cells) and the GP imaging technique to study cholesterol
removal from the plasma membrane by rHDL and methyl beta cyclo
dextrines (MβCD). When human erythrocytes are incubated with
3.5 mM MβCD for 2 h at 37 °C, approximately 90% of the total
cholesterol [97] is removed, inducing a decrease in GP of 0.1 unit
(Fig. 8A). The same decrease in GP is obtained when erythrocytes are
incubated with 300 µg/ml rHDL for 2 h at 37 °C. As seen in the images
in Fig. 8A, we found that MβCD induces changes in shape of the cells
(Fig. 8A, second image from the left) as previously reported [94].
Instead, the use of rHDL as cholesterol acceptor was less damaging for
the cells and changes in shape were not observed (Fig. 8A, third image
from the left). Incubation of HeLa cells with 10 mMMβCD for 60 min
[98] induces the same changes in GP as incubation with 300 µg/ml
rHDL for 2 h at 37 °C. Both types of cells shown in Fig. 8 lack
(erythrocytes) or have minor (HeLa cells) expression of the ABCA1
transporter. Studies done by our group [99] using CHO (Chinese
Hamster Ovary) cells (which express ABCA1) show a similar behavior
than the one described for erythrocytes and HeLa. Nevertheless, as
cells were not previously loaded with cholesterol, it is possible that
ABCA1 was not highly activated under our experimental conditions.
Interestingly, working with HeLa overexpressing ABCA1, Zarubica et
al. [100] reported that overexpression of functional ABCA1 triggers
not only apoA-I but MβCD-mediated cholesterol efﬂux. They
attributed this fact to a participation of ABCA1 in the redistribution
of membrane-associated cholesterol into pools readily accessible to
external acceptors.
The fact that GP imaging of the plasma membrane does not show
macrodomain separation still leaves open the possibility that domains
are smaller than the pixel size. If domains smaller than the pixel size
indeed exist in cell membranes, the mechanism behind the decrease
in GP value when cholesterol is removed (Fig. 8) has to be explained
considering that the average membrane GP measured corresponds to
GP = GPld × fldð Þ + GPlo × floð Þ
where GPld, GPlo, and fld, flo are the GP and the fraction (number of
pixels) of the ld and lo phases, respectively [63]. Thus, the average GP
value measured in the membrane is the result of cholesterol
equilibrium between the membrane and the internal cholesterol
storage, etc. Further studies are needed to understand the cellular
mechanism behind these observations in relation to lipid segregation
in cell membranes and the connection between the changes in
membrane ﬂuidity and cholesterol equilibrium.
Acknowledgement
The work presented here was supported by funds from the
National Institutes of Health (Grants PHS 5 P41 RR-03155 and P50-
GM076516 US) for S.A.S., G.O., and E.G.; the ANPCyT, Argentina, Grant
Nos. 14443 and PICT 2106-2008 to M.A.T.; and the Australian FABLS
No. R108 and International Cooperation (CONICET) toM.A.T. and S.A.S.
We acknowledge Dr. W.S. Davidson (U. Cincinatti, OH) and Dr. A.M.O.Gomes (Federal University of Rio de Janeiro, Brazil) for the kind
donation of the apoA-I mutant H1@H4 and HeLa cells, respectively.
References
[1] M. Hao, S. Mukherjee, F.R. Maxﬁeld, PNAS 98 (2001) 13072–13077.
[2] K. Simons, E. Ikonen, Nature 387 (1997) 569–572.
[3] D. Lichtenberg, F.M. Goñi, H. Heerklotz, Trends Biochem. Sci. 30 (2005) 430–436.
[4] L.C. Silva, A.H. Futerman, M. Prieto, Biophys. J. 96 (2009) 3210–3222.
[5] K. Jacobson, O.G. Mouritsen, R.G.W. Anderson, Nat. Cell Biol. 9 (2007) 7–14.
[6] S. Munro, Cell 115 (2003) 377–388.
[7] T.J. McIntosh, A. Vidal, S.A. Simon, Biophys. J. 85 (2003) 1656–1666.
[8] A.K. Groen, R.P. Oude Elferink, H.J. Verkade, F. Kuipers, Ann. Med. 36 (2004)
135–145.
[9] J.-R. Nofer, M. Walter, G. Assmann, Expert Rev. Cardiovasc. Ther. 3 (2005)
1071–1086.
[10] X.-Q. Wang, A.S. Paller, J. Invest. Dermatol. 126 (2006) 951–953.
[11] D.J. Rader, E.T. Alexander, G.L. Weibel, J. Billheimer, G.H. Rothblat, J. Lipid Res. 50
(2009) S189–S194.
[12] Y. Yamauchi, C.C.Y. Chang, M. Hayashi, S. Abe-Dohmae, P.C. Reid, T.-Y. Chang, S.
Yokoyama, J. Lipid Res. 45 (2004) 1943–1951.
[13] A.M. Vaughan, J.F. Oram, J. Lipid Res. 47 (2006) 2433–2443.
[14] P.J. Barter, Atheroscler. Suppl. 3 (2002) 39–47.
[15] D.J. Gordon, B.M. Rifkind, N. Engl. J. Med. 321 (1989) 1311–1316.
[16] M. Guha, D.L. Gantz, O. Gursky, J. Lipid Res. 49 (2008) 1752–1761.
[17] G. Cavigiolio, B. Shao, E.G. Geier, G. Ren, J.W. Heinecke, M.N. Oda, Biochemistry
47 (2008) 4770–4779.
[18] B. Shao, G. Cavigiolio, N. Brot, M.N. Oda, J.W. Heinecke, Proc. Natl. Acad. Sci. U. S.
A. 105 (2008) 12224–12229.
[19] M. Navab, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, B.J. Ansell, A.M.
Fogelman, Nat. Clin. Pract. Endocrinol. Metab. 2 (2006) 504–511.
[20] B. Hansel, A. Kontush, D. Bonnefont-Rousselot, E. Bruckert, M.J. Chapman, Curr.
Atheroscler. Rep. 8 (2006) 501–509.
[21] Y.D. Landry, M. Denis, S. Nandi, S. Bell, A.M. Vaughan, X. Zha, J. Biol. Chem. 281
(2006) 36091–36101.
[22] A.J. Mendez, G. Lin, D.P. Wade, R.M. Lawn, J.F. Oram, J. Biol. Chem. 276 (2001)
3158–3166.
[23] W. Drobnik, H. Borsukova, A. Böttcher, A. Pfeiffer, G. Liebisch, G.L. Schütz, H.
Schindler, G. Schmitz, Trafﬁc 3 (2002) 268–278.
[24] C.M. Rosetti, B. Maggio, Biophys. J. 93 (2007) 4254–4267.
[25] M.I. Angelova, D.S. Dimitrov, Faraday Discuss. Chem. Soc. 81 (1986) 303–311.
[26] T. Pott, H. Bouvrais, P. Méléard, Chem. Phys. Lipids 154 (2008) 115–119.
[27] L.R. Montes, A. Alonso, F.M. Goñi, L.A. Bagatolli, Biophys. J. 93 (2007) 3548–3554.
[28] Y. Sun, M. Hao, Y. Luo, C.-P. Liang, D.L. Silver, C. Cheng, F.R. Maxﬁeld, A.R. Tall, J.
Biol. Chem. 278 (2003) 5813–5820.
[29] K. Simons, G. van Meer, Biochemistry 27 (1988) 6197–6202.
[30] D. Brown, Braz. J. Med. Biol. Res. 27 (1994) 309–315.
[31] L.A. Bagatolli, S.A. Sanchez, T.L. Hazlett, E. Gratton, Methods Enzymol. 360 (2003)
481–500.
[32] S.L. Veatch, S.L. Keller, Biophys. J. 85 (2003) 3074–3083.
[33] D.A. Brown, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10517–10518.
[34] S.L. Veatch, S.L. Keller, Phys. Rev. Lett. 89 (2002) 268101.
[35] S.L. Veatch, S.L. Keller, Phys. Rev. Lett. 94 (2005) 148101.
[36] S.A. Sanchez, L.A. Bagatolli, E. Gratton, T.L. Hazlett, Biophys. J. 82 (2002)
2232–2243.
[37] C. Nicolini, J. Baranski, S. Schlummer, J. Palomo, M. Lumbierres-Burgues, M.
Kahms, J. Kuhlmann, S.A. Sánchez, E. Gratton, H. Waldmann, R. Winter, J. Am.
Chem. Soc. 128 (2006) 192–201.
[38] L.A. Bagatolli, D.D. Binns, J.M. Jameson, J.P. Albanesi, J. Protein Chem. 21 (2002)
383–391.
[39] K.M. Berland, P.T.C. So, E. Gratton, Biophys. J. 68 (1995) 694–701.
[40] N.L. Thompson, Topics in Fluorescence SpectroscopyJ. R. Lakowicz, 1991, pp. 337–378.
[41] Y. Chen, J.D. Muller, K.M. Berland, E. Gratton, Methods 19 (1999) 234–252.
[42] N.L. Thompson, A.M. Lieto, N.W. Allen, Curr. Opin. Struct. Biol. 12 (2002)
634–641.
[43] M.K. Levin, J.H. Carson, Differentiation 72 (2004) 1–10.
[44] B.R. Masters, P.T. So, K.H. Kim, C. Buehler, E. Gratton, Methods Enzymol. 307
(1999) 513–536.
[45] G.J. Brakenhoff, M. Muller, R.I. Ghauharali, J. Microscopy 183 (1996) 140–144.
[46] P.T.C. So, T. French, W.M. Yu, K.M. Berland, C.Y. Dong, E. Gratton, in: X.F. Wang, B.
Herman (Eds.), Fluoresc. Imaging Spectrosc. Microsc., 1996, pp. 351–374.
[47] Y. Chen, J.D. Müller, P.T.C. So, E. Gratton, Biophys. J. 77 (1999) 553–567.
[48] K.M. Berland, P.T.C. So, Y. Chen, W.W. Mantulin, E. Gratton, Biophys. J. 71 (1996)
410–420.
[49] Q. Ruan, M.A. Cheng, M. Levi, E. Gratton, W.W. Mantulin, Biophys. J. 87 (2004)
1260–1267.
[50] A. Celli, S. Beretta, E. Gratton, Biophys. J. 94 (2008) 104–116.
[51] A. Garcia-Marcos, S.A. Sánchez, P. Parada, J.S. Eid, D.M. Jameson, M. Remacha, E.
Gratton, J.P.G. Ballesta, Biophys. J. 94 (2008) 2884–2890.
[52] M. Digman, P. Sengupta, S.P. Wiseman, C.M. Brown, A.R. Horwitz, E. Gratton,
Biophys. J. 88 (2005) 33–36.
[53] M.A. Digman, R.B. Dalal, A.R. Horwitz, E. Gratton, Biophys. J. 94 (2008)
2320–2332.
[54] R.B. Dalal, M.A. Digman, A.R. Horwitz, V. Vetri, E. Gratton, Microsc. Res. Tech. 71
(2008) 69–81.
1408 S.A. Sánchez et al. / Biochimica et Biophysica Acta 1798 (2010) 1399–1408[55] K. Krishnan, O. Holub, E. Gratton, A.H.A. Clayton, S. Cody, P.D.J. Moens, Biophys. J.
96 (2009) 5112–5121.
[56] R.C. Patel, U. Kumar, D.C. Lamb, J.S. Eid,M. Rocheville, M. Grant, A. Rani, T.L. Hazlett,
S.C. Patel, E. Gratton, Y.C. Patel, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3294–3299.
[57] M.A. Digman, P.W. Wiseman, C.K. Choi, A.R. Horwitz, E. Gratton, Proc. Natl. Acad.
Sci. U. S. A. 106 (2009) 2170–2175.
[58] M.A. Digman, E. Gratton, WIREs Syst. Biol. Med. 1 (2009) 273–282.
[59] M. Inoue, M.A. Digman, M.A. Cheng, S.Y. Breusegem, N. Halaihel, V. Sorribas, W.
W. Mantulin, E. Gratton, N.P. Barry, M. Levi, J. Biol. Chem. 279 (2004)
49160–49171.
[60] G. Weber, F.J. Farris, Biochemistry 18 (1979) 3075–3078.
[61] T.S. Parasassi, G. DeStasio, G. Ravagnan, R. Rusch, E. Gratton, Biophys. J. 60 (1991)
179–189.
[62] T. Parasassi, E. Gratton, J. Fluorescence 8 (1995) 365–373.
[63] S.A. Sánchez, M.A. Tricerri, G. Gunther, E. Gratton, Modern Research and
Educational Topics in Microscopy, in: A. Mendez-Vilas, Diaz (Eds.), Applications
in Physical/Chemical Sciences, 2007, pp. 1007–1014.
[64] T. Parasassi, E.K. Krasnowska, L.A. Bagatolli, E. Gratton, J. Fluorescence 8 (1998)
365–373.
[65] M.F. Henning, S.A. Sánchez, L. Bakás, Biochem. Biophys. Res. Commun. 383
(2009) 22–26.
[66] S. Janosch, C. Nicolini, B. Ludolph, C. Peters, M. Volkert, T.L. Hazlet, E. Gratton, H.
Waldmann, R. Winter, J. Am. Chem. Soc. 126 (2004) 7496–7503.
[67] N. Kahya, D. Brown, P. Schwille, Biochemistry 44 (2005) 7479–7489.
[68] M.A. Tricerri, J.D. Toledo, S.A. Sanchez, T.L. Hazlett, E. Gratton, A. Jonas, H.A.
Garda, J. Lipid Res. 46 (2005) 669–678.
[69] S.A. Sánchez, M.A. Tricerri, E. Gratton, J. Lipid Res. 48 (2007) 1689–1700.
[70] M.A. Tricerri, S.A. Sanchez, C. Arnulphi, D.M. Durbin, E. Gratton, A. Jonas, J. Lipid
Res. 43 (2002) 187–197.
[71] N. Puff, A. Lamaziere, M. Seigneuret, G. Trugnan, M. Angelova, Chem. Phys. Lipids
133 (2005) 195–202.
[72] C. Arnulphi, S.A. Sánchez, M.A. Tricerri, E. Gratton, A. Jonas, Biophys. J. 89 (2005)
285–295.
[73] H.J. Pownall, J.B. Massey, S.K. Kusserow, A.M. Gotto Jr., Biochemistry 17 (1978)
1183–1188.
[74] L.A. Bagatolli, E. Gratton, Biophys. J. 77 (1999) 2090–2101.
[75] S.G. Clerc, T.E. Thompson, Biophys. J. 68 (1995) 2333–2341.
[76] J.B. Swaney, J. Biol. Chem. 255 (1980) 8791–8797.[77] C.G.Brouillette,G.M.Anantharamaiah,Biochim.Biophys. Acta 1256 (1995)103–129.
[78] S.E. Panagotopulos, S.R. Witting, E.M. Horace, D.Y. Hui, J.N. Maiorano, W.S.
Davidson, J. Biol. Chem. 277 (2002) 39477–39484.
[79] D.P. Rogers, L.M. Roberts, J. Lebowitz, G. Datta, G.M. Anantharamaiah, J.A. Engler,
C.G. Brouillette, Biochemistry 37 (1998) 11714–11725.
[80] A. Jonas, Methods Enzymol. 128 (1986) 553–582.
[81] J.C. Phillips,W.Wriggers, Z. Li, A. Jonas,K. Schulten, Biophys. J. 73 (1997)2337–2346.
[82] J.P. Segrest, M.K. Jones, A.E. Klon, C.J. Sheldahl, M. Hellinger, D.H. eLoof, S.C.
Harvey, J. Biol. Chem. 274 (1999) 31755–31758.
[83] M.A. Tricerri, A.K.B. Agree, S.A. Sanchez, J. Bronski, A. Jonas, Biochemistry 40
(2001) 5065–5074.
[84] M.N. Palgunachari, V.K.Mishra, S. Lund-Katz,M.C. Phillips, S.O.Adeyeye, S. Alluri, G.M.
Anantharamaiah, J.P. Segrest, Arterioscler. Thromb. Vasc. Biol. 16 (1996) 328–338.
[85] K.H. Cho, D.M. Durbin, A. Jonas, J. Lipid Res. 42 (2001) 379–389.
[86] G.H. Rothblat, M. de la Llera-Moya, V. Atger, J. Lipid Res. 40 (1999) 781–796.
[87] M.C. Phillips, K.L. Gillotte, M.P. Haynes, W.J. Johnson, S. Lund-Katz, G.H. Rothblat,
Atherosclerosis 137 (1998) 13–17.
[88] S.L. Veatch, I.V. Polozov, K. Gawrisch, S.L. Keller, Biophys. J. 86 (2004) 2910–2922.
[89] R.E. Brown, J. Cell Sci. 111 (1998) 1–9.
[90] D. Needham, T.J. McIntosh, E. Evans, Biochemistry 27 (1988) 4668–4673.
[91] M.B. Sankaram, T.E. Thompson, Proc. Natl. Acad. Sci. U. S. A. 88 (1991)
8686–8690.
[92] J.S. Harris, D.E. Epps, S.R. Davio, F.J. Kezdy, Biochemistry 34 (1995) 3851–3857.
[93] L.J. Pike, J. Lipid Res. 47 (2006) 1597–1598.
[94] B.M. Stott, M.P. Vu, C.O. McLemore, M.S. Lund, E. Gibbons, T.J. Brueseke, H.A.
Wilson-Ashworth, J.D. Bell, J. Lipid Res. 49 (2008) 1202–1215.
[95] S.K. Smith, A.R. Farnbach, F.M. Harris, A.C. Hawes, L.R. Jackson, A.M. Judd, R.S.
Vest, S. Sanchez, J.D. Bell, J. Biol. Chem. 276 (2001) 22732–22741.
[96] K. Gaus, E. Gratton, E.P. Kable, A.S. Jones, I. Gelissen, L. Kritharides, W. Jessup,
Proc. Natl. Acad. Sci. USA 100 (2003) 15554–15559.
[97] K.S. Giddings, A.E. Johnson, R.K. Tweten, Proc. Natl. Acad. Sci. U. S. A. 100 (2003)
11315–11320.
[98] I. Kansau, C. Berger, M. Hospital, R. Amsellem, V. Nicolas, A.L. Servin, M.F. Bernet-
Camard, Infect. Immun. 72 (2004) 3733–3742.
[99] M.S. Jaureguiberry, M.A. Tricerri, S.A. Sanchez, H.A. Garda, G.S. Finarelli, M.C.
Gonzalez, O.J. Rimoldi, J. Membr. Biol. 234 (2010) 183–194.
[100] A. Zarubica, A.P. Plazzo, M. Stöckl, T. Trombik, Y. Hamon, P. Müller, T. Pomorski,
A. Herrmann, G. Chimini, FASEB J. 23 (2009) 1775–1785.
